![Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy. - Abstract - Europe PMC Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy. - Abstract - Europe PMC](https://europepmc.org/articles/PMC3378255/bin/cn-2011-00128x_0006.jpg)
Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy. - Abstract - Europe PMC
The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence
C7β-Methyl Analogues of the Orvinols: The Discovery of Kappa Opioid Antagonists with Nociceptin/Orphanin FQ Peptide (NOP) Receptor Partial Agonism and Low, or Zero, Efficacy at Mu Opioid Receptors | Journal of Medicinal
![Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists](https://www.frontiersin.org/files/Articles/447554/fphar-10-00407-HTML/image_m/fphar-10-00407-g001.jpg)
Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
![Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling](https://www.science.org/cms/asset/35d59cc9-5e24-4990-b0eb-4fc248e3274c/9_ra117_f1.gif)
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
![Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA) Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)](https://nida.nih.gov/sites/default/files/styles/content_image_medium/public/images/valenza_zamarripa_promo.jpg?itok=HRbtRBEw)
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
![Development of Functionally Selective, Small Molecule Agonists at Kappa Opioid Receptors - ScienceDirect Development of Functionally Selective, Small Molecule Agonists at Kappa Opioid Receptors - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0021925820553611-gr1.jpg)
Development of Functionally Selective, Small Molecule Agonists at Kappa Opioid Receptors - ScienceDirect
![La FDA degli Stati Uniti approva l'innovativo agonista periferico del recettore oppioide Kappa (KOR) Korsuva! - Notizie del settore - Notizie - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd La FDA degli Stati Uniti approva l'innovativo agonista periferico del recettore oppioide Kappa (KOR) Korsuva! - Notizie del settore - Notizie - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd](http://it.hspchem.com/Content/uploads/2021524038/20210913162501ac357b6b0aa241a087558b2827205601.jpg)
La FDA degli Stati Uniti approva l'innovativo agonista periferico del recettore oppioide Kappa (KOR) Korsuva! - Notizie del settore - Notizie - Hefei Home Sunshine Pharmaceutical Technology Co., Ltd
![Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA) Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)](http://nida.nih.gov/sites/default/files/images/valenza_zamarripa_fig1.gif)
Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)
![Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists](https://www.frontiersin.org/files/Articles/447554/fphar-10-00407-HTML/image_m/fphar-10-00407-g003.jpg)
Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
![Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling](https://www.science.org/cms/10.1126/scisignal.aai8441/asset/af19b0d1-3407-4f21-8f6d-9bcb1eddc0cd/assets/graphic/9_ra117_f2.jpeg)
Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria | Science Signaling
![Kappa-opioid receptor agonist U50448H protects against renal ischemia-reperfusion injury in rats via activating the PI3K/Akt signaling pathway | Acta Pharmacologica Sinica Kappa-opioid receptor agonist U50448H protects against renal ischemia-reperfusion injury in rats via activating the PI3K/Akt signaling pathway | Acta Pharmacologica Sinica](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Faps.2017.51/MediaObjects/41401_2018_Article_BFaps201751_Fig1_HTML.jpg)
Kappa-opioid receptor agonist U50448H protects against renal ischemia-reperfusion injury in rats via activating the PI3K/Akt signaling pathway | Acta Pharmacologica Sinica
![Hyperalgesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Hyperalgesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update](https://www.globaldata.com/store/wp-content/uploads/sites/2/2022/04/Hyperalgesia-pipeline-drugs-market-by-targets.png)